Non-cytotoxic drug treatment o

Chinese medical Tribune (resident reporter Zhu Fang) from Sichuan University West China hospital digestive Medicine Professor Tang Chengwei, application of modern testing technology, multiple perspective gastric, mucosa-associated lymphoid tissue (MALT) Lymphoma biological characteristics, filter out non-cytotoxic drugs for the treatment of gastric cancer and new, which a controlled clinical trial clinical comprehensive treatment of gastric cancer.　　　Related research in 2009, Chinese medical science and technology progress second prize. Researchers from gastric cancer treatment difficulties starting and current treatment, first studied biological behavior in gastric, non-cytotoxic drugs while filtering out somatostatin analogues and selective cyclooxygenase 2 (COX-2) inhibitor, exploring the treatment human gastric cancer theory basis and mechanism.　　　On this basis, proposed a new treatment options. Researchers report the somatostatin analogue Octreotide through inhibition of mitogen-activated protein kinase signaling pathways, matrix protein kinase-2 expression and tumor angiogenesis, including stem cell growth, invasion and metastasis of gastric cancer.　　　The results have been confirmed by other researchers. Researchers found that of Octreotide combined with COX-2 inhibitors, can effectively enhance its extracellular signal-regulated kinase (ERK)-1, ERK-2, original cancer gene c-fos, inhibition of Activator protein-1 and growth inhibition of gastric cancer Xenografts in nude mice.　　　The researchers also found that the application meloxicam long-term large dose COX-2 inhibitors in gastric cancer cell line, is not resistant. The researchers found that preoperative Octreotide combined with celecoxib and can increase gene expression such as NAG-1 and E-Cad, inducing tumor cell apoptosis, reduced cancer microvessel density, increased cancer tissue and fibrous tissue hyperplasia. Patient no significantly adverse reactions occurred, good compliance.　　　Accordingly, researchers have proposed a new programme of comprehensive treatment of gastric cancer-a non-cytotoxic drug +D2 radical surgery + chemotherapy and be approved by the Chinese clinical trial registration center clinical multicenter controlled trial. Status against that early diagnosis difficult, step in Clinical pathological diagnosis scheme proposed by researchers and sequential therapeutic strategies, made some clinical effect.